Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 4(2)

Phase 2(1)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03651752Phase 3Terminated

DPCP for the Treatment of Alopecia Areata

Role: collaborator

NCT00167102Not ApplicableCompleted

Alefacept in Patients With Severe Scalp Alopecia Areata

Role: collaborator

NCT00069589Active Not Recruiting

Alopecia Areata Registry

Role: collaborator

NCT00484679Phase 2Completed

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

Role: collaborator

NCT00176943Phase 4Completed

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

Role: collaborator

NCT00177021Phase 4Completed

Aldara for the Treatment of Extensive Alopecia Areata

Role: collaborator

All 6 trials loaded